Sánchez, Ricardo
Dorado, Sara
Ruíz-Heredia, Yanira
Martín-Muñoz, Alejandro
Rosa-Rosa, Juan Manuel
Ribera, Jordi
García, Olga
Jimenez-Ubieto, Ana
Carreño-Tarragona, Gonzalo
Linares, María
Rufián, Laura
Juárez, Alexandra
Carrillo, Jaime
Espino, María José
Cáceres, Mercedes
Expósito, Sara
Cuevas, Beatriz
Vanegas, Raúl
Casado, Luis Felipe
Torrent, Anna
Zamora, Lurdes
Mercadal, Santiago
Coll, Rosa
Cervera, Marta
Morgades, Mireia
Hernández-Rivas, José Ángel
Bravo, Pilar
Serí, Cristina
Anguita, Eduardo
Barragán, Eva
Sargas, Claudia
Ferrer-Marín, Francisca
Sánchez-Calero, Jorge
Sevilla, Julián
Ruíz, Elena
Villalón, Lucía
del Mar Herráez, María
Riaza, Rosalía
Magro, Elena
Steegman, Juan Luis
Wang, Chongwu
de Toledo, Paula
García-Gutiérrez, Valentín
Ayala, Rosa
Ribera, Josep-Maria
Barrio, Santiago
Martínez-López, Joaquín
Funding for this research was provided by:
FUNDACION CRIS CONTRA EL CÁNCER
Article History
Received: 23 February 2022
Accepted: 22 July 2022
First Online: 29 July 2022
Change Date: 28 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-57570-5
Competing interests
: JML received research funding from Incyte, Celgene, Janssen, Novartis and BMS. JML is also on the speaking bureau of Incyte, Celgene, Janssen, Novartis and BMS. FF received research funding from Incyte and Cty. RS, YR, SB, AJ and LR are employees and SB, JML and RA are equity shareholders of Altum Sequencing Co. The remaining co-authors declare no competing financial interests.